Chase Ladd
YOU?
Author Swipe
View article: Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials Open
Supplementary Figure S1: Flow diagram for study inclusion.
View article: Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials Open
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
View article: Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials Open
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehen…
View article: An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study
An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study Open
Background: Cancer drug development is a complex and costly process. Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma. Despite initially…
View article: Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials
Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials Open
Background Vemurafenib (Zelboraf®, Roche), approved by the FDA in 2011 for unresectable and metastatic melanoma and Erdheim-Chester Disease, has been explored in trials for other BRAF-mutated cancers. Despite 12 years of clinical use, the …
View article: Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials Open
Purpose: Our study aimed to evaluate the risk and benefit profiles of clinical trials using abiraterone in cancer treatment.Materials and Methods: A comprehensive search was conducted on May 24, 2023, using databases such as PubMed, Embase…
View article: Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications Open
These results are consistent with other studies that present similar findings, such as in Carlisle et al which indicate limited efficacy in nonapproved indications. Future trials should keep this potential evidence and patient burden in mi…
View article: Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials
Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials Open
Objective This study aims to evaluate published clinical trials of ramucirumab to assess the risk/benefit profile and burden over time for patients. Background The burden of oncologic drug development on patients paired with increasing cli…
View article: Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review Open
Our paper evaluated the effectiveness of lenvatinib for its FDA-approved indications; however, expansion of clinical trials into novel indications was characterized by diminished efficacy, while patients experienced a high burden of advers…
View article: Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials
Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials Open
Objective Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug. Background Creating a novel chemotherapy is costly both in time and capital spen…
View article: Evaluating the underreporting of patient-reported outcomes in carpal tunnel syndrome randomized controlled trials
Evaluating the underreporting of patient-reported outcomes in carpal tunnel syndrome randomized controlled trials Open
Context In recent years, patient-centered healthcare has become a primary concern for researchers and healthcare professionals. When included in randomized controlled trials (RCTs), patient-reported outcome (PRO) measures serve a critical …
View article: REPORTING OF PATIENT-REPORTED OUTCOMES IN RCTS FOCUSED ON TINNITUS: A META STUDY
REPORTING OF PATIENT-REPORTED OUTCOMES IN RCTS FOCUSED ON TINNITUS: A META STUDY Open
Background The inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) supplements outcomes of treatment efficacy with the patient’s perspectives. The aim of this study was to evaluate reporting completeness of…
View article: Table of Contents
Table of Contents Open